N. Kachuck

发表

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

G. Barger, S. Reingold, C. Bever, 2000, Multiple sclerosis.

When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis

N. Kachuck, 2011, Neuropsychiatric disease and treatment.

Registries, research, and regrets: is the FDA’s post-marketing REMS process not adequately protecting patients?

N. Kachuck, 2011, Therapeutic advances in neurological disorders.

Sustained release oral fampridine in the treatment of multiple sclerosis

N. Kachuck, 2009, Expert opinion on pharmacotherapy.

Sustainedreleaseoralfampridine inthetreatmentofmultiple sclerosis

N. Kachuck, 2009 .

Immunological aspects of secondary progressive multiple sclerosis

L. Weiner, W. Gilmore, B. Lund, 2002 .

ETHICAL PERSPECTIVES IN NEUROLOGY: ETHICAL CONSIDERATIONS WHEN DOCTOR AND PATIENT PERSPECTIVES ON TREATMENT RISKS DIFFER

N. Kachuck, J. Conway, 2010, Continuum.

Characterization of monoclonal antibodies to human OC43.

J. Fleming, J. Keck, S. Stohlman, 1987, Advances in experimental medicine and biology.

Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis

J. Sejvar, J. Correale, P. Narayanaswami, 2019, Neurology.

Challenges and opportunities: what we are learning from the clinical natalizumab experience

N. Kachuck, 2005, Expert review of neurotherapeutics.

Randomized controlled trial of atorvastatin in clinically isolated syndrome

A. Cross, A. Bar-Or, E. Rosenberg, 2012, Neurology.

Increased CXCL8 (IL-8) expression in Multiple Sclerosis

S. Groshen, L. Weiner, W. Stohl, 2004, Journal of Neuroimmunology.

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.

D. Arnold, L. Weiner, A. Bar-Or, 2007, Archives of neurology.

Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1352458509358088

J. Wolinsky, H. Panitch, A. Goodman, 2022 .

MONITORING DISEASE PROGRESSION: INCORPORATING MRI AND NEW MODALITIES IN CLINICAL DECISION MAKING *

M. Racke, N. Kachuck, 2008 .

The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

N. Putzki, V. Limmroth, N. Kachuck, 2011, Therapeutic advances in neurological disorders.

different interferon beta formulations alone or in combination efficacious ?

N. Putzki, V. Limmroth, N. Kachuck, 2011 .

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

D. Goodin, M. Filippi, P. Calabresi, 2004, Neurology.

The utility of MRI in suspected MS

S. L. Galetta, D. Goodin, M. Filippi, 2003, Neurology.

Medical decisions are not just about the facts: What a life-threatening virus can teach us about empathy, psychology, and the practice of neurology

N. Kachuck, 2012, Neurology. Clinical practice.

Patient participation in treatment decision-making in the nursing home: the issue of competence.

L. Fitten, A. Steinberg, N. Kachuck, 1986, The gerontologist.

Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial

D. Arnold, L. Weiner, A. Bar-Or, 2007 .

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

J. Wolinsky, H. Panitch, C. Ford, 2006, Multiple sclerosis.

The utility of MRI in suspected MS

D. Goodin, M. Filippi, P. Calabresi, 2003, Neurology.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

C. Bever, L. Weiner, J. Wolinsky, 2000, Multiple Sclerosis.